Patents Assigned to SERB
-
Patent number: 11873525Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: January 16, 2024Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11845977Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: May 23, 2023Date of Patent: December 19, 2023Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11274331Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11274332Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 15, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11268128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: October 15, 2021Date of Patent: March 8, 2022Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 11060128Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: September 1, 2020Date of Patent: July 13, 2021Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 10793893Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.Type: GrantFiled: June 29, 2012Date of Patent: October 6, 2020Assignee: SERB SAInventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
-
Patent number: 8604066Abstract: A medication, a pharmaceutical composition, and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).Type: GrantFiled: September 28, 2011Date of Patent: December 10, 2013Assignee: SERBInventors: Frédéric J. Baud, Pascal Houze, Maya Kayouka
-
Publication number: 20120041037Abstract: A medication, a pharmaceutical composition, and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).Type: ApplicationFiled: September 28, 2011Publication date: February 16, 2012Applicant: SERBInventors: Frédéric J. BAUD, Pascal HOUZE, Maya KAYOUKA
-
Publication number: 20090156650Abstract: This invention relates to a medication, a pharmaceutical composition. and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).Type: ApplicationFiled: September 19, 2008Publication date: June 18, 2009Applicant: SERBInventors: Frederic BAUD, Pascal HOUZE, Maya KAYOUKA
